These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 8630906)

  • 1. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
    Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
    Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coinduction of granulocyte-macrophage colony-stimulating factor release and lymphokine-activated killer cell susceptibility in monocytes by interleukin-2 via interleukin-2 receptor beta.
    Epling-Burnette PK; Wei S; Blanchard DK; Spranzi E; Djeu JY
    Blood; 1993 Jun; 81(11):3130-7. PubMed ID: 8499646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
    Singh SM; Sone S; Inamura N; Ogura T
    Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients.
    Takahashi K; Saito S; Kamamura Y; Katakawa M; Monden Y
    Cancer Immunol Immunother; 2000 Dec; 49(10):537-43. PubMed ID: 11129324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of recombinant human granulocyte-macrophage colony-stimulating factor on the induction of lymphokine-activated killer cells in vitro.
    Okamura S; Tanaka T; Yamaga S; Omori F; Niho Y
    Int J Immunopharmacol; 1991; 13(5):587-93. PubMed ID: 1783473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
    Horton SA; Oldham RK; Yannelli JR
    Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killing of alveolar macrophages and of monocytes that have responded to granulocyte-macrophage colony-stimulating factor by human lymphokine-activated killer cells.
    Sone S; Inamura N; Singh SM; Okubo A; Yanagawa H; Nakanishi M; Ogura T
    Jpn J Cancer Res; 1989 Jul; 80(7):662-9. PubMed ID: 2507489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
    Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
    J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer cell regulation of T-cell-mediated immunity to Candida albicans.
    Wei S; Blanchard DK; McMillen S; Djeu JY
    Infect Immun; 1992 Sep; 60(9):3586-95. PubMed ID: 1500166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of neuronal cells by culture supernatant of T lymphocytes triggered by anti-CD3 mAb followed by propagation in the presence of interleukin-2.
    Ishiguro M; Okada A; Asai K; Kojima K; Okada H
    Microbiol Immunol; 2016 Jan; 60(1):47-55. PubMed ID: 26616436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
    Provinciali M; Di Stefano G; Stronati S; Fabris N
    Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Ohno T
    J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.
    Takahashi K; Sone S; Saito S; Kamamura Y; Uyama T; Ogura T; Monden Y
    Jpn J Cancer Res; 1995 Sep; 86(9):861-6. PubMed ID: 7591964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses.
    Baxevanis CN; Tsavaris NB; Papadhimitriou SI; Zarkadis IK; Papadopoulos NG; Bastounis EA; Papamichail M
    Eur J Cancer; 1997 Jul; 33(8):1202-8. PubMed ID: 9301443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).
    Masucci G; Ragnhammar P; Wersäll P; Mellstedt H
    Cancer Immunol Immunother; 1990; 31(4):231-5. PubMed ID: 2199042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function.
    Swisher SG; Economou JS; Holmes EC; Golub SH
    Cell Immunol; 1990 Jul; 128(2):450-61. PubMed ID: 2113430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.